Related Experiment Video

Updated: May 24, 2026

Biochemical Measurement of Neonatal Hypoxia
13:13

Biochemical Measurement of Neonatal Hypoxia

Published on: August 24, 2011

An evidence-based view on hyperbilirubinaemia

Peter H Dijk1, Christian V Hulzebos

  • 1Department of Neonatology, Beatrix Children's Hospital, University Medical Center Groningen, Hanzeplein 1, Groningen, the Netherlands. p.h.dijk@umcg.nl

Acta Paediatrica (Oslo, Norway : 1992)
|March 13, 2012
PubMed

Insights

Severe jaundice in newborns can cause lifelong issues, but is often preventable. Updated clinical guidelines are crucial for healthcare professionals to effectively manage infant hyperbilirubinemia.

Area of Science:

  • Neonatal Medicine
  • Pediatrics
  • Evidence-Based Medicine

Background:

  • Jaundice in newborn infants is a common condition requiring careful management.
  • Existing evidence on the care of jaundiced newborns was reviewed.
  • Severe hyperbilirubinemia can lead to preventable, lifelong consequences for affected children.

Purpose of the Study:

  • To review current evidence on the management of neonatal jaundice.
  • To identify the need for updated guidelines in hyperbilirubinemia care.

Main Methods:

  • A literature search was conducted for relevant reviews and randomized controlled trials (RCTs).
  • Six Cochrane reviews, eight other reviews, and eighteen recent RCTs were included in the analysis.

Main Results:

  • The review synthesized findings from multiple high-quality evidence sources.
  • Significant evidence exists regarding the prevention and treatment of neonatal jaundice.

Conclusions:

  • Despite available evidence, many infants suffer preventable long-term consequences from severe hyperbilirubinemia.
  • There is an urgent need for clear, evidence-based guidelines to aid healthcare professionals in preventing, diagnosing, and treating infant hyperbilirubinemia.
Abstract

More Related Videos

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice07:48

A Silver Nanoparticle Method for Ameliorating Biliary Atresia Syndrome in Mice

Published on: October 13, 2018

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Rh Blood Group01:19

Rh Blood Group

The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.